Clinical Trials Logo

Actinic Keratoses clinical trials

View clinical trials related to Actinic Keratoses.

Filter by:

NCT ID: NCT04843553 Completed - Actinic Keratoses Clinical Trials

Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients: A Pilot Study

NICE
Start date: October 14, 2016
Phase: Early Phase 1
Study type: Interventional

Skin cancers and pre-cancerous growths (called actinic keratoses, "AKs"), that aren't melanomas, develop in patients with a kidney transplant at excessive rates. When these pre-cancerous AKs, and "non-melanoma" skin cancers occur in kidney transplant patients, they tend to be aggressive, and require frequent medical procedures, often surgery, for the removal of the skin cancers. If not removed adequately the pre-cancers can develop into skin cancers, and the skin cancers, if not removed, may spread, and even cause death. Reducing the occurrence and complications of these skin cancers and pre-cancers in kidney transplant patients with a safe, effective, well-tolerated treatment taken by mouth would be an important medical advance. We are testing oral nicotinamide (NAM)-a B-vitamin compound-for that purpose. Approximately fifty kidney transplant patients who have had at least one non-melanoma skin cancer in the past, will be given randomized to receive NAM, 1 gram twice daily by mouth, or identical pills without NAM, and followed for 1 year to see if NAM treatment reduces the numbers of pre-cancerous AKs, and non-melanoma skin cancers they develop. Patients will be asked to come to the clinic for 3 follow up visits (every 4 months for up to 12 months). They will receive a full body skin exam by a dermatologist, have detailed counting of AKs and biopsies for any suspicious lesions as standard of care. Blood will also be drawn as well as a urine sample obtained at each visit for safety assessment and storage. We will also ask them to answer a series of questions about dietary patterns and intake of whole foods and supplements.

NCT ID: NCT04842422 Not yet recruiting - Actinic Keratoses Clinical Trials

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

NCT ID: NCT04814953 Enrolling by invitation - Clinical trials for Squamous Cell Carcinoma

HRQoL Keratinocyte Carcinomas

Start date: July 1, 2020
Phase:
Study type: Observational

Rationale: Keratinocyte skin cancer is known to influence the HRQoL in a specific way. Derived utility values are required for cost-effectiveness analyses of new interventions. However there is no sensitive tool to capture HRQoL that translates into utilities available. Objective: To document the exact HRQoL in patients with in KC using the generic EQ-5D-5L questionnaire, as well as the TTO, 15D and the BaSQoL questionnaire, and to develop health utilities based on these tools. Study design: Longitudinal observational study (at time 0 and time 0 +12 months). Study population: Patients aged ≥18 years consulting a dermatologist or their GP for diagnosis, treatment or follow-up of a (pre)malignant skin lesion(s).

NCT ID: NCT04809662 Recruiting - Actinic Keratoses Clinical Trials

Comparing Immune Responses to Topical Imiquimod

Start date: March 16, 2021
Phase:
Study type: Observational

The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.

NCT ID: NCT04642287 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 2022
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-FU cream in Organ Transplant Recipients (OTRs) to determine if it can stimulate the immune cells against actinic keratoses precancerous skin lesions after transplantation and prevent cutaneous squamous cell carcinoma (SCC) in long-term.

NCT ID: NCT04527653 Recruiting - Actinic Keratoses Clinical Trials

Evaluation of The Efficacy and Safety of Tixel Treatment for the Treatment of Facial and/or Scalp Actinic Keratoses

Start date: May 14, 2020
Phase: N/A
Study type: Interventional

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

NCT ID: NCT04482322 Recruiting - Actinic Keratoses Clinical Trials

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

VDAK
Start date: January 13, 2020
Phase: N/A
Study type: Interventional

This is a prospective clinical trial in which 30 patients will receive a brief (5-day or 14-day) supplementation with 10,000 IU of Vitamin D, prior to receiving aminolevulinic acid (ALA)- blue light PDT for the treatment of actinic keratoses (AKs).

NCT ID: NCT04429308 Not yet recruiting - Actinic Keratoses Clinical Trials

PDT vs Peels for AKs

Start date: January 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to to compare photodynamic therapy (PDT) versus the combination of Jessner's solution and 35% trichloroacetic acid (TCA) chemical peels for the treatment of actinic keratoses on upper extremities. This is a randomized clinical trial. Approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives Jessner's solution followed immediately by 35% TCA. AKs will be counted before treatment and 2-8 weeks after treatment. This study is a pilot study designed to determine the feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

NCT ID: NCT04329221 Not yet recruiting - Skin Cancer Clinical Trials

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial aims to investigate the efficacy of Calcipotriol ointment combined with 5-fluorouracil cream as an immunotherapy for actinic keratosis in Organ Transplant Recipients (OTRs) before transplantation and determine whether it can prevent cutaneous squamous cell carcinoma (SCC) in OTRs post-transplant.

NCT ID: NCT04319159 Completed - Actinic Keratoses Clinical Trials

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Start date: March 5, 2020
Phase: Phase 1
Study type: Interventional

The aim of this study is to assess the pharmacokinetics (PK) of the parent drug 5-aminolevulinic acid (ALA) and its active metabolite protoporphyrin IX (PpIX) during photodynamic therapy with 3 tubes of BF-200 ALA 10% gel (Ameluz®) in combination with the BF-RhodoLED® lamp in the systemic circulation of diseased individuals presenting with actinic keratosis (AK) on the face/scalp or in the periphery (neck/trunk/extremities) along with subjects' safety/tolerability during and after treatment.